Ataxia Telangiectasia Mutated Proteins
"Ataxia Telangiectasia Mutated Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of PROTEIN-SERINE-THREONINE KINASES which activate critical signaling cascades in double strand breaks, APOPTOSIS, and GENOTOXIC STRESS such as ionizing ultraviolet A light, thereby acting as a DNA damage sensor. These proteins play a role in a wide range of signaling mechanisms in cell cycle control.
| Descriptor ID |
D064007
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.097 D12.776.157.687.125 D12.776.660.720.125
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ataxia Telangiectasia Mutated Proteins".
Below are MeSH descriptors whose meaning is more specific than "Ataxia Telangiectasia Mutated Proteins".
This graph shows the total number of publications written about "Ataxia Telangiectasia Mutated Proteins" by people in this website by year, and whether "Ataxia Telangiectasia Mutated Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 3 | 5 |
| 2021 | 4 | 2 | 6 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 1 | 2 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ataxia Telangiectasia Mutated Proteins" by people in Profiles.
-
Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer. J Biol Chem. 2021 Jan-Jun; 296:100382.
-
ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways. EMBO J. 2020 07 15; 39(14):e104036.
-
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351.
-
Genetic variations in the homologous recombination repair pathway genes modify risk of glioma. J Neurooncol. 2016 Jan; 126(1):11-17.
-
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov. 2015 Jul; 5(7):752-67.
-
miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014 Dec 05; 5:5671.
-
Phosphorylation of the BRCA1 C terminus (BRCT) repeat inhibitor of hTERT (BRIT1) protein coordinates TopBP1 protein recruitment and amplifies ataxia telangiectasia-mutated and Rad3-related (ATR) Signaling. J Biol Chem. 2014 Dec 05; 289(49):34284-95.
-
ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014 Sep; 16(9):864-75.
-
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014 Jul 30; 5(14):5637-50.
-
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014 Aug 28; 124(9):1460-72.